NasdaqGM - Nasdaq Real Time Price ? USD Structure Therapeutics Inc. (GPCR) Follow Compare 39.50 -0.12 (-0.30%) At close: October 18 at 4:00 PM EDT 39.50 0.00 (0.00%) After hours: October 18 at 4:05 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Structure Therapeutics (GPCR): Innovating Oral Therapies for Obesity and Diabetes We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Structure Therapeutics (NASDAQ:GPCR) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatility that indicates how much the price of […] Insider Monkey ? 4 days ago GPCR -0.30% ^GSPC Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect? The consensus price target hints at an 115.8% upside potential for Structure Therapeutics Inc. Sponsored ADR (GPCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. Zacks ? 10 days ago GPCR -0.30% As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position. Investor's Business Daily ? 16 days ago PFE LLY VKTX Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now? We recently compiled a list of 10 Best Young Stocks To Buy Now. In this article, we will look at where Structure Therapeutics Inc. (NASDAQ:GPCR) ranks among the best young stocks to buy now. Market Uncertainty to Remain Until Elections A broader market trend observed ever since the Fed announced its September cut rate has […] Insider Monkey ? 21 days ago GPCR -0.30% ^GSPC High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people lose weight in the mid-stage study, but Leerink Partners called the magnitude “underwhelming,” and analysts noted that some patients had anxiety and other neuropsychiatric side effects. Its stock-price decline underscores just how closely investors are following the industry race to develop a weight-loss pill that may be less expensive and easier to manufacture than injected drugs like Wegovy and Eli Lilly’s Zepbound. The Wall Street Journal ? 29 days ago VKTX NONOF NVO Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September GlobeNewswire ? last month GPCR -0.30% NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data. Zacks ? last month NVO LLY VKTX Structure Therapeutics Inc. (GPCR): Among the Best Mid-Cap Healthcare Stocks To Buy Now We recently compiled a list of the 10 Best Mid-Cap Healthcare Stocks To Buy Now. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands against the other mid-cap healthcare stocks. Global Healthcare Market: Growth Projections, Challenges, and Tech-Driven Innovations According to projections by ReportLinker, the market for healthcare […] Insider Monkey ? last month GPCR -0.30% Structure Therapeutics Appoints Angus C. Russell to Board of Directors Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industrySAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the appointment of Angus C. Russell to its board of directors. Mr. Russell previously served as Chief Executive Officer of GlobeNewswire ? last month GPCR -0.30% Structure Therapeutics Announces Participation in Upcoming Investor Conferences SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced management will participate at the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceFireside chat: Thursday, September 5 at 10:00 a.m. EDT Cantor Fitzgerald Global Healthcare Conference 2024Firesi GlobeNewswire ? last month GPCR -0.30% Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... Simply Wall St. ? 2 months ago GPCR -0.30% 3 Promising Biotech Stocks for the Long-Term: August 2024 Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly (NYSE:LLY), for example. The last time I mentioned LLY, I said, “Oversold shares of Eli Lilly could easily bounce higher on sales of its obesity drugs. And it could easily jump higher with its Zepbound drug being considered for the treatment of sleep apnea.” That was on July 30, as the stock traded at about $780. Today, it’s already up to $893.04 and could easily push aggressively higher t InvestorPlace ? 2 months ago LLY GPCR -0.30% VKTX Don’t Forget This Start-Up’s Weight-Loss Pill, Analyst Says Structure Therapeutics could find a strategic partner for its promising drug, stock could nearly triple Barrons.com ? 2 months ago GPCR -0.30% ROG.SW LLY Why Are Hedge Funds Bullish on Structure Therapeutics Inc. (GPCR) Now? We recently compiled a list of the 10 Best GLP-1 and Weight Loss Stocks to Buy Now. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands against the other GLP-1 and weight loss stocks. According to WHO, more than one billion people worldwide are obese, including 650 million […] Insider Monkey ? 2 months ago GPCR -0.30% Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights GSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter of 2024 Oral small molecule amylin receptor agonist development candidate expected to be selected in the fourth quarter of 2024 Obesity pipeline consists of four oral small molecule programs targeting GLP-1, GIP, amylin and APJ receptors Strong financial position with cash balance of $927.1 million expected to fund projected operations and key clinical milestones through at least 2027 SAN FRANCISCO, Aug. 08, 2024 (GLO GlobeNewswire ? 2 months ago GPCR -0.30% 3 Biotech Stocks That Could Make Your Summer Unforgettable If you want to do well with biotech stocks, trade the anticipation of news. Look at Structure Therapeutics (NASDAQ:GPCR), for example. On March 8, I learned that GPCR would report Phase 2a 12-week obesity drug data in the second quarter of the year. Knowing that Phase 1 trials had positive results, I anticipated that Phase 2 results could be just as solid — all as we got closer to the data being released on June 3. At the time, GPCR traded at about $36.80. InvestorPlace - Stock Market News, Stoc InvestorPlace ? 2 months ago GPCR -0.30% LLY SNDX What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings? Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release. Zacks ? 2 months ago GPCR -0.30% Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX), and Structure Therapeutics Inc (NASDAQ:GPCR) stocks are trading lower on Wednesday. What happened? Earlier on Wednesday, Roche Holdings AG (OTC:RHHBY) announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for type 2 diabetes and obesity. The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinic Benzinga ? 3 months ago VKTX GPCR -0.30% NVO The 3 Most Undervalued Biotech Stocks to Buy in July 2024 There’s always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow. In fact, according to Grand View Research, biotech could be worth about $3.88 trillion by 2030. After all, there’s always going to be a need for biotech. Fueling even more upside is artificial intelligence, which may be able to create new drugs that can treat untreatable issues. There’s even newer innovation, demand for better treatment, pharmaceutical companies strengthening pipelines, g InvestorPlace ? 3 months ago VKTX GPCR -0.30% The 3 Smartest Biotech Stocks to Buy With $5K Right Now With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs. Just look at Eli Lilly (NYSE:LLY). The company is seeing so much demand it’s spending $5.3 billion to make even more Mounjaro and Zepbound. According to The Wall Street Journal, Zepbound alone is generating more than 74,800 prescriptions every week in the U.S. No wonder shares of LLY exploded from a January low of about $580 to $901.26.InvestorPlace - Stock Market News, InvestorPlace ? 3 months ago GPCR -0.30% LLY VKTX Performance Overview Trailing total returns as of 10/20/2024, which may include dividends or other distributions. Benchmark is MSCI WORLD Return GPCR MSCI WORLD YTD -3.09% +18.42% 1-Year -41.01% +32.87% 3-Year +58.00% +33.05%
